新的成像方法可检测可检测肝癌肝

StephenW

New imaging method spots liver cancer at early stage
INS
New York, | 15 May, 2015



US researchers have developed a new imaging method that can detect liver cancer and other liver diseases at an earlier stage than what current leading methods can, reports a new study.

"Liver cancers associated with high mortality rates and poor treatment responses are often diagnosed in the late stages because there is not a reliable way to detect primary liver cancer and metastasis at a size smaller than one centimetre," said lead study author Jenny Yang, professor at Georgia State University, in the US.

The new method can scan liver tumours that measure less than 0.25 millimetres, the study reported.

Magnetic resonance imaging (MRI) is the leading imaging technique to detect disease without using radiation. MRI contrast or imaging agents aid MRI techniques to obtain tissue-specific images.

However, according to the researchers the applications of MRI contrast agents are not effective for early detection of cancerous tumours because they are hampered by uncontrolled blood circulation time, low relaxation rate or sensitivity, and low specificity.

Most contrast agents, Yang said, are rapidly excreted from the liver, not allowing sufficient time to obtain quality imaging.

To more effectively detect cancerous tumors at an early stage, the researchers developed a new class of protein-based contrast agents (PRCAs) and an imaging methodology that provides robust results for the early detection of liver cancer and other liver diseases.

"Our new agents can obtain both positive and negative contrast images within one application, providing double the accuracy and confidence of locating cancerous tumors," Yang said.

The researchers have shown proof-of-concept that the new method can be used to detect cancerous liver tumours at an early stage with high sensitivity.

They have also demonstrated that these new agents better aid the imaging of multiple organs, including the kidney and blood vessels, in addition to the liver and tumours.

The findings were published in the journal Proceedings of the National Academy of Sciences.

Read more at http://www.thestatesman.com/news ... 87jMzbbMc2Qci6xJ.99

StephenW

新的成像方法掩护肝癌早期
INS
纽约| 2015年5月15日



美国的研究人员已经开发出可检测肝癌等肝脏疾病在比目前能领先的方法，报道一项新的研究的早期阶段，一个新的成像方法。

“与高死亡率和贫困治疗反应相关的肝癌往往在确诊的晚期，因为没有一个可靠的方法来检测原发性肝癌和转移，在尺寸比1厘米小，说：”研究的主要作者杨珍妮，教授在佐治亚州立大学，在美国。

这种新方法可以扫描测量小于0.25毫米肝脏肿瘤的研究报告。

磁共振成像（MRI）是一种领先的成像技术来检测疾病而不使用辐射。 MRI造影或成像剂辅助MRI技术以获得组织特异性的图像。

但是，根据研究人员，因为它们是由不受控制的血液循环时间，低松弛率或灵敏度和低特异性阻碍MRI造影剂的应用并不有效早期检测癌性肿瘤。

大多数造影剂，杨洁篪表示，正在迅速从肝脏排出体外，不留出足够的时间，以获得高质量成像。

为了更有效地检测出癌性肿瘤在早期阶段，研究人员开发了一类新的基于蛋白质的造影剂（PRCAs）和成像方法，它提供了强大的结果的早期检测肝癌等肝脏疾病的。

“我们的新代理可以在一个应用程序获得的正面和负面对比度的图像，提供双精度和定位癌性肿瘤的信心，”杨说。

的研究人员已经证明证明的概念，新的方法可用于检测癌肝肿瘤在具有高灵敏度的早期阶段。

他们还表明，这些新的药物更好帮助多个器官的成像，包括肾脏和血管，除肝脏和肿瘤。

这项研究结果发表在美国国家科学院的期刊论文。

更多详情http://www.thestatesman.com/news/science-and-tech/new-imaging-